Taken together, the findings indicate that the lectin pathway of the complement system, resistin, MIF, and AA metabolism may serve as promising targets for ITP treatment, offering novel perspectives on potential therapeutic interventions. This evidence concerns the gene MIF and autoimmune thrombocytopenic purpura.